Published in Adv Drug Deliv Rev on March 26, 2009
Delivery of siRNA therapeutics: barriers and carriers. AAPS J (2010) 2.15
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Delivery of therapeutic proteins. J Pharm Sci (2010) 1.58
Progress in microRNA delivery. J Control Release (2013) 1.58
Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem (2011) 1.32
Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials (2010) 1.29
Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. ACS Nano (2011) 1.17
Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. Angew Chem Int Ed Engl (2011) 1.13
Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug Chem (2010) 1.11
Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res (2009) 1.11
Overcoming nonviral gene delivery barriers: perspective and future. Mol Pharm (2013) 1.10
A rapid pathway toward a superb gene delivery system: programming structural and functional diversity into a supramolecular nanoparticle library. ACS Nano (2010) 1.10
Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angew Chem Int Ed Engl (2011) 1.07
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Quantum dot-based theranostics. Nanoscale (2009) 1.03
Quantitative evaluation of siRNA delivery in vivo. RNA (2010) 1.03
Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol Ther (2011) 1.02
Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. EPMA J (2010) 1.01
Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem (2011) 0.99
Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv (2010) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther (2012) 0.98
The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res (2013) 0.97
Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics (2014) 0.96
The chemistry and biology of oligonucleotide conjugates. Acc Chem Res (2012) 0.95
Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J Histochem Cytochem (2011) 0.92
RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel) (2013) 0.92
Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. J Control Release (2014) 0.91
Versatile RNA interference nanoplatform for systemic delivery of RNAs. ACS Nano (2014) 0.91
Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release (2013) 0.91
Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells. Int J Nanomedicine (2013) 0.90
Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther (2014) 0.90
Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors. J Pharm Innov (2014) 0.89
Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm (2011) 0.89
Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability. AAPS J (2011) 0.89
Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. J Control Release (2013) 0.87
Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate. Mol Pharm (2012) 0.87
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials (2014) 0.85
miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem (2014) 0.84
Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. Tissue Eng Part A (2012) 0.84
Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev (2015) 0.83
Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides. Bioconjug Chem (2013) 0.83
Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale (2014) 0.83
Non-viral nanocarriers for siRNA delivery in breast cancer. J Control Release (2014) 0.83
Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model. Mol Ther Nucleic Acids (2016) 0.82
The delivery of therapeutic oligonucleotides. Nucleic Acids Res (2016) 0.82
Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. J Control Release (2015) 0.82
Biomimetic RNA-silencing nanocomplexes: overcoming multidrug resistance in cancer cells. Angew Chem Int Ed Engl (2014) 0.82
Dendrimers for siRNA Delivery. Pharmaceuticals (Basel) (2013) 0.82
Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. J Urol (2015) 0.82
Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release (2013) 0.81
Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol (2011) 0.81
A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. Nat Protoc (2014) 0.81
Quantitative silencing of EGFP reporter gene by self-assembled siRNA lipoplexes of LinOS and cholesterol. Mol Pharm (2012) 0.81
Effect of surface properties on liposomal siRNA delivery. Biomaterials (2015) 0.80
Adaptive amphiphilic dendrimer-based nanoassemblies as robust and versatile siRNA delivery systems. Angew Chem Int Ed Engl (2014) 0.80
Nanoparticle ligand presentation for targeting solid tumors. AAPS PharmSciTech (2014) 0.80
Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. J Nanobiotechnology (2013) 0.80
Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J Histochem Cytochem (2013) 0.79
Nanomedicine: Silence the target. Nat Nanotechnol (2009) 0.79
Expression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vector. PLoS One (2011) 0.79
Agile delivery of protein therapeutics to CNS. J Control Release (2014) 0.79
Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy. Angew Chem Int Ed Engl (2016) 0.78
Immunotherapy of hepatocellular carcinoma with small double-stranded RNA. BMC Cancer (2014) 0.78
Conjugation of palmitic acid improves potency and longevity of siRNA delivered via endosomolytic polymer nanoparticles. J Biomed Mater Res A (2015) 0.78
Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon. Theranostics (2015) 0.78
Multi-level kinetic model of mRNA delivery via transfection of lipoplexes. PLoS One (2014) 0.77
Urocanic acid-modified chitosan nanoparticles can confer anti-inflammatory effect by delivering CD98 siRNA to macrophages. Colloids Surf B Biointerfaces (2016) 0.77
Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA. Pharmaceuticals (Basel) (2011) 0.77
Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. J Control Release (2015) 0.77
Molecular recognition enables nanosubstrate-mediated delivery of gene-encapsulated nanoparticles with high efficiency. ACS Nano (2014) 0.77
Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nat Commun (2016) 0.76
Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy. Theranostics (2016) 0.76
A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes. Acta Pharm Sin B (2014) 0.76
Self-Assembled Lipoplexes of Short Interfering RNA (siRNA) Using Spermine-Based Fatty Acid Amide Guanidines: Effect on Gene Silencing Efficiency. Pharmaceutics (2011) 0.76
Redox-based control of the transformation and activation of siRNA complexes in extracellular environments using ferrocenyl lipids. J Am Chem Soc (2013) 0.76
Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. ACS Nano (2017) 0.76
Highlighting the role of polymer length, carbohydrate size, and nucleic acid type in potency of glycopolycation agents for pDNA and siRNA delivery. Biomacromolecules (2013) 0.75
Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel) (2016) 0.75
Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system. Int J Nanomedicine (2017) 0.75
Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems. Kona (2016) 0.75
Surface-mediated delivery of siRNA from fibrin hydrogels for knockdown of the BMP-2 binding antagonist noggin. Acta Biomater (2015) 0.75
Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis. Immunology (2016) 0.75
Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. J Colloid Interface Sci (2016) 0.75
Barriers to Liposomal Gene Delivery: from Application Site to the Target. Iran J Pharm Res (2016) 0.75
Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep (2017) 0.75
Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Ther (2016) 0.75
Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Lett (2017) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 35.49
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 26.12
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol (2009) 19.99
Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 19.15
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell (2004) 16.10
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell (2005) 15.26
Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell (2002) 14.37
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev (2002) 10.71
Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell (1990) 10.56
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 8.63
A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A (2002) 8.57
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther (1999) 8.28
Single processing center models for human Dicer and bacterial RNase III. Cell (2004) 8.19
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA (2006) 7.06
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59
Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 6.49
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
Effective expression of small interfering RNA in human cells. Nat Biotechnol (2002) 6.02
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
RNA interference in adult mice. Nature (2002) 5.33
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther (1999) 5.17
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
Total silencing by intron-spliced hairpin RNAs. Nature (2000) 4.78
Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem (2003) 4.40
Heritable gene silencing in Drosophila using double-stranded RNA. Nat Biotechnol (2000) 4.37
Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today (2006) 4.35
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (1996) 4.06
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med (2005) 4.04
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes. Nat Genet (2000) 3.79
Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol (2002) 3.42
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther (2005) 3.28
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
siRNA and miRNA: an insight into RISCs. Trends Biochem Sci (2005) 3.25
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A (2002) 3.21
The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol (2003) 3.17
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 3.15
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J (2003) 3.09
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Human immunodeficiency virus type 1 escape from RNA interference. J Virol (2003) 3.01
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00
A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res (2000) 2.99
Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A (2003) 2.91
Off-target effects by siRNA can induce toxic phenotype. RNA (2006) 2.89
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther (2005) 2.68
Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.64
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods (2004) 2.38
Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A (2003) 2.37
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther (2001) 2.35
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 2.29
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev (2002) 2.27
Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci U S A (2005) 2.23
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther (2006) 2.21
Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials (2009) 2.13
Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol (2002) 2.04
Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A (2002) 2.00
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med (2004) 1.91
Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell (2003) 1.88
RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A (2003) 1.84
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol (2002) 1.80
Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad Sci U S A (1992) 1.80
Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res (2004) 1.79
Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res (2006) 1.78
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release (2010) 1.64
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. Int J Pharm (2003) 1.46
Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci (2006) 1.46
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem (2010) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol (2007) 1.24
A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano (2013) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Development of non-viral vectors for systemic gene delivery. J Control Release (2002) 1.21
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther (2005) 1.19
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther (2011) 1.15
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm (2005) 1.11
Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci (2010) 1.10
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother (2007) 1.08
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release (2013) 1.08
HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release (2004) 1.08
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med (2002) 1.03
Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release (2008) 1.03
Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm (2010) 1.02
Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother (2005) 1.01
Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther (2005) 1.01
Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res (2012) 1.00
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials (2013) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol (2004) 0.98
Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano (2014) 0.97
Recent advances in intravesical drug/gene delivery. Mol Pharm (2006) 0.97
Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96
The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials (2012) 0.94
Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol (2004) 0.93
Cross-linked polyvinylpyrrolidone nanoparticles: a potential carrier for hydrophilic drugs. J Colloid Interface Sci (2003) 0.93
Noninvasive gene delivery to the liver by mechanical massage. Hepatology (2002) 0.92
A syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol Ther (2002) 0.92
Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol Ther (2005) 0.92
Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res (2004) 0.92
Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res (2003) 0.91
Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology (2003) 0.91
Non-immunostimulatory nonviral vectors. FASEB J (2004) 0.91
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano (2014) 0.91
Lipid-protamine-DNA-mediated antigen delivery. Curr Drug Deliv (2005) 0.90
Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials (2013) 0.90
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs (2008) 0.90
Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int (2007) 0.90
Enhanced cutaneous gene delivery following intradermal injection of naked DNA in a high ionic strength solution. Mol Ther (2002) 0.89
Recent advances in non-viral gene delivery. Adv Genet (2005) 0.89
Thermosensitive hydrogel as a Tgf-beta1 gene delivery vehicle enhances diabetic wound healing. Pharm Res (2003) 0.88
Non-viral vector as vaccine carrier. Adv Genet (2005) 0.88
Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm (2008) 0.88
Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology (2003) 0.87
Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol Ther (2007) 0.87
Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved. J Gene Med (2006) 0.87
Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release (2011) 0.87
Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother (2011) 0.86
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv (2008) 0.86
Mechanism of naked DNA clearance after intravenous injection. J Gene Med (2007) 0.86
Recent Advances in Non-viral Gene Delivery. Adv Genet (2005) 0.85
Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm (2010) 0.85
Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem (2012) 0.84
Mechanism of liver gene transfer by mechanical massage. Mol Ther (2004) 0.84
Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res (2004) 0.84
Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol Pharm (2006) 0.84
Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther (2002) 0.84
How does the cell overcome LCP nanoparticle-induced calcium toxicity? Mol Pharm (2013) 0.83
Cancer immunotherapy and nanomedicine. Pharm Res (2010) 0.83
Gene transfer to subdermal tissues via a new gene gun design. Hum Gene Ther (2003) 0.83
Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res (2002) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Preparation, characterization and in vitro drug release studies of novel polymeric nanoparticles. Int J Pharm (2006) 0.83
Novel nonviral vectors target cellular signaling pathways: regulated gene expression and reduced toxicity. J Pharmacol Exp Ther (2007) 0.82
Using hydrophilic ionic liquid, [bmim]BF4-ethylene glycol system as a novel media for the rapid synthesis of copper nanoparticles. PLoS One (2012) 0.82
Smart polymeric nanoparticles for cancer gene delivery. Mol Pharm (2015) 0.82
Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release (2013) 0.81
Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. Am J Respir Cell Mol Biol (2002) 0.81